Literature DB >> 22961165

The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk?

Jay W Heinecke1.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22961165     DOI： 10.1038/nm.2930

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  10 in total

1.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL.

Authors:  Tomas Vaisar; Subramaniam Pennathur; Pattie S Green; Sina A Gharib; Andrew N Hoofnagle; Marian C Cheung; Jaeman Byun; Simona Vuletic; Sean Kassim; Pragya Singh; Helen Chea; Robert H Knopp; John Brunzell; Randolph Geary; Alan Chait; Xue-Qiao Zhao; Keith Elkon; Santica Marcovina; Paul Ridker; John F Oram; Jay W Heinecke
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

2.  HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events.

Authors:  Robert S Rosenson; H Bryan Brewer; M John Chapman; Sergio Fazio; M Mahmood Hussain; Anatol Kontush; Ronald M Krauss; James D Otvos; Alan T Remaley; Ernst J Schaefer
Journal:  Clin Chem       Date:  2011-01-25       Impact factor: 8.327

3.  The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?

Authors:  Daniel J Rader; Alan R Tall
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

4.  High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

Authors:  Rachel H Mackey; Philip Greenland; David C Goff; Donald Lloyd-Jones; Christopher T Sibley; Samia Mora
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

5.  High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase.

Authors:  A M Bérard; B Föger; A Remaley; R Shamburek; B L Vaisman; G Talley; B Paigen; R F Hoyt; S Marcovina; H B Brewer; S Santamarina-Fojo
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

6.  Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology.

Authors:  B Trigatti; H Rayburn; M Viñals; A Braun; H Miettinen; M Penman; M Hertz; M Schrenzel; L Amigo; A Rigotti; M Krieger
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

7.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.

Authors:  Amit V Khera; Marina Cuchel; Margarita de la Llera-Moya; Amrith Rodrigues; Megan F Burke; Kashif Jafri; Benjamin C French; Julie A Phillips; Megan L Mucksavage; Robert L Wilensky; Emile R Mohler; George H Rothblat; Daniel J Rader
Journal:  N Engl J Med       Date:  2011-01-13       Impact factor: 91.245

8.  The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages.

Authors:  Margarita de la Llera-Moya; Denise Drazul-Schrader; Bela F Asztalos; Marina Cuchel; Daniel J Rader; George H Rothblat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01-14       Impact factor: 8.311

9.  Combined statin and niacin therapy remodels the high-density lipoprotein proteome.

Authors:  Pattie S Green; Tomas Vaisar; Subramaniam Pennathur; J Jacob Kulstad; Andrew B Moore; Santica Marcovina; John Brunzell; Robert H Knopp; Xue-Qiao Zhao; Jay W Heinecke
Journal:  Circulation       Date:  2008-09-02       Impact factor: 29.690

Review 10.  HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis.

Authors:  Alan R Tall; Laurent Yvan-Charvet; Naoki Terasaka; Tamara Pagler; Nan Wang
Journal:  Cell Metab       Date:  2008-05       Impact factor: 27.287
  10 in total
  31 in total

Review 1.  Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions.

Authors:  Alan Chait; Ira Goldberg
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

2.  Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity.

Authors:  Tomáš Vaisar; Chongren Tang; Ilona Babenko; Patrick Hutchins; Jake Wimberger; Anthony F Suffredini; Jay W Heinecke
Journal:  J Lipid Res       Date:  2015-05-20       Impact factor: 5.922

3.  Restoration of renal function does not correct impairment of uremic HDL properties.

Authors:  Chantal Kopecky; Michael Haidinger; Ruth Birner-Grünberger; Barbara Darnhofer; Christopher C Kaltenecker; Gunther Marsche; Michael Holzer; Thomas Weichhart; Marlies Antlanger; Johannes J Kovarik; Johannes Werzowa; Manfred Hecking; Marcus D Säemann
Journal:  J Am Soc Nephrol       Date:  2014-07-28       Impact factor: 10.121

4.  Old HDL learns a new (anti-inflammatory) trick.

Authors:  Justin I Odegaard; Ajay Chawla
Journal:  Nat Immunol       Date:  2014-02       Impact factor: 25.606

Review 5.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

Review 6.  Why targeting HDL should work as a therapeutic tool, but has not.

Authors:  Mary G Sorci-Thomas; Michael J Thomas
Journal:  J Cardiovasc Pharmacol       Date:  2013-09       Impact factor: 3.105

7.  AIBP protects against metabolic abnormalities and atherosclerosis.

Authors:  Dina A Schneider; Soo-Ho Choi; Colin Agatisa-Boyle; Laurence Zhu; Jungsu Kim; Jennifer Pattison; Dorothy D Sears; Philip L S M Gordts; Longhou Fang; Yury I Miller
Journal:  J Lipid Res       Date:  2018-03-20       Impact factor: 5.922

Review 8.  Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?

Authors:  Baohai Shao; Jay W Heinecke
Journal:  Expert Rev Proteomics       Date:  2017-11-13       Impact factor: 3.940

9.  HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients.

Authors:  Chantal Kopecky; Sanam Ebtehaj; Bernd Genser; Christiane Drechsler; Vera Krane; Marlies Antlanger; Johannes J Kovarik; Christopher C Kaltenecker; Mojtaba Parvizi; Christoph Wanner; Thomas Weichhart; Marcus D Säemann; Uwe J F Tietge
Journal:  J Am Soc Nephrol       Date:  2016-09-09       Impact factor: 10.121

10.  Liver ABCA1 deletion in LDLrKO mice does not impair macrophage reverse cholesterol transport or exacerbate atherogenesis.

Authors:  Xin Bi; Xuewei Zhu; MyNgan Duong; Elena Y Boudyguina; Martha D Wilson; Abraham K Gebre; John S Parks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-06-27       Impact factor: 8.311
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.